Insights from 2023 ESMO Asia Annual Meeting
ESMO Asia 2023 Insights: "Efficacy & Safety of MCLA-129, an Anti-EGFR/c-MET Bispecific Antibody, Combined With Osimertinib, as 1L Therapy or After Progression on Osimertinib in NSCLC"
Login to view comments.
Click here to Login
